Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.
Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.
Frasca
Denis
D
INSERM, ERI-23, Pôle Biologie Santé, 40 Avenue du Recteur Pineau, Poitiers, France.
Marchand
Sandrine
S
Petitpas
Franck
F
Dahyot-Fizelier
Claire
C
Couet
William
W
Mimoz
Olivier
O
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077727:Ertapenem; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods*; D055104:Infusions, Subcutaneous / Q000379:methods*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D055815:Young Adult; D047090:beta-Lactams / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D000077727:Ertapenem